Bristol Myers Squibb Q3 FY2026 results
$63.43+1.78%
Bristol Myers Squibb reported revenue of $13.1 billion, up 6.9% from a year earlier, net income of $2.16 billion and diluted earnings per share of $1.05 against $1.08 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 29 Oct 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $13.07B | $12.22B | +6.9% |
| Gross profit | $8.92B | $8.79B | +1.5% |
| Gross margin | 68.3% | 71.9% | −3.6 pts |
| Operating income | $2.84B | $3.01B | −5.4% |
| Operating margin | 21.8% | 24.6% | −2.8 pts |
| Net income | $2.16B | $2.20B | −1.8% |
| Diluted EPS | $1.05 | $1.08 | −2.8% |
| Operating cash flow | $4.18B | $6.31B | −33.8% |
| Capital expenditure | $344.0M | $320.0M | +7.5% |
| Free cash flow | $3.84B | $5.99B | −36.0% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| International revenues | $4.0B | up 2.6% |
| Gross product sales | $18.0B | down 20.1% |
| Net product sales | $12.6B | up 6.4% |
| Growth Portfolio revenue | $7.7B | up 11.7% |
| Legacy Portfolio revenue | $5.4B | up 0.9% |
| Eliquis revenue | $4.7B | up 25.2% |
| Opdivo revenue | $2.4B | down 6.2% |
| Orencia revenue | $983.0M | up 2.0% |
| Yervoy revenue | $793.0M | up 7.3% |
| Reblozyl revenue | $750.0M | up 22.0% |
| Breyanzi revenue | $526.0M | up 46.5% |
| Alliance and other revenues | $463.0M | up 24.5% |
| Camzyos revenue | $420.0M | up 41.9% |
| Opdualag revenue | $367.0M | up 22.7% |
| Opdivo Qvantig revenue | $334.0M | up 398.5% |
| Revlimid revenue | $303.0M | down 47.3% |
| Zeposia revenue | $168.0M | up 4.3% |
| Pomalyst/Imnovid revenue | $130.0M | down 80.7% |
| Sotyktu revenue | $100.0M | up 25.0% |
| Alliance revenues | $95.0M | down 24.0% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $13.07B | +6.9% | $1.05 |
| Q2 FY2026 | 30 Jun 2026 | $12.97B | +5.7% | $1.62 |
| Q1 FY2026 | 31 Mar 2026 | $11.49B | +2.6% | $1.31 |
| Q4 FY2025 | 31 Dec 2025 | $12.50B | +1.3% | $0.53 |
| Q3 FY2025 | 30 Sep 2025 | $12.22B | +2.8% | $1.08 |
| Q2 FY2025 | 30 Jun 2025 | $12.27B | +0.6% | $0.64 |
| Q1 FY2025 | 31 Mar 2025 | $11.20B | −5.6% | $1.20 |
| Q4 FY2024 | 31 Dec 2024 | $12.34B | +7.5% | $0.04 |
More on Bristol Myers Squibb: financial statements · revenue · earnings per share
BMY's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.